38.84 +2.06 (+5.59%)
Delayed Data USD Disclaimer

UCB SA ADR Company Profile

Equity Type
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company’s primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson’s disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; BIMZELX for treating psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; and dapirolizumab pegol for systemic lupus erythematosus. In addition, the company is involved in developing rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan to treat myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam to treat tereotypical prolonged seizure; Bepranemab to treat Alzheimer’s disease; and UCB0599 to treat Parkinson's disease. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. It operates in the United States, Japan, Germany, rest of Europe, Spain, France, China, Italy, the United Kingdom, Ireland, Belgium, and internationally. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.
Contact Information
Brussels,1070 Belgium
32 2 559 99 99
32 2 559 99 00
Top Executives
Jean-Christophe Tellier 63 2014 CEO & Executive Director
Jonkheer Cédric van Rijckevorsel 52 2014 Director
Charles-Antoine Emmanuel T. Janssen 51 2012 Director
Albrecht De Graeve 67 2010 Director
Cyril Janssen 51 2015 Director
Ulf Arne Wiinberg 64 2016 Independent Director
Pierre L. Gurdjian 61 2016 Independent Director
Karel Boone 80 2000 Honorary Chairman
Mark Eyskens 0 2005 Honorary Chairman
Gerhard N. Mayr 77 2005 Honorary Chairman
Georges Jacobs de Hagen 83 2005 Honorary Chairman
Diégo du Monceau de Bergendal 73 1984 Honorary Chairman
Jonathan M. Peacock 65 2021 Independent Chair of the Board
Fiona du Monceau 45 2021 Vice-Chair of the Board
Dame Kay Davies 72 2014 Independent Director
Jan Berger 66 2019 Independent Director
Susan Gasser 68 2021 Independent Director
Gaëtan van de Werve 0 2006 Honorary Director
Arnoud de Pret Roose de Calesberg 79 2005 Honorary Director
Prince Lorenz 0 2001 Honorary Director
Peter J. Fellner 80 2005 Honorary Director
Guy Keutgen 0 1990 Honorary Director
Jean van Rijckevorsel 0 1992 Honorary Director
Jean-Pierre Kinet 70 2008 Honorary Director
Jean-Louis Vanherweghem 0 0000 Honorary Director
Alice Dautry 73 2015 Honorary Director
Alan John Blinken 0 0000 Honorary Director
Frederic Roch Doliveux 67 2005 Honorary Director
Thomas Fulton Wilson McKillop 80 2009 Honorary Director
Norman J. Ornstein 75 2008 Honorary Director
Maelys Castella 57 2023 Independent Director
Clear All
Please try another search

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Related Articles